Patient Characteristics and Medication Utilization Patterns of Infliximab-Treated Rheumatoid Arthritis Patients Subsequently Transitioned to Intravenous Golimumab

被引：0
|
作者：
Ellis, Lorie A. [1 ]
DeHoratius, Raphael J. [2 ,3 ]
Kafka, Shelly [2 ]
Varker, Helen [4 ]
Brouillette, Matthew [4 ]
Malangone-Monaco, Elisabetta [4 ]
机构：
[1] Janssen Sci Affairs LLC, Hlth Econ & Outcomes Res, Horsham, PA USA
[2] Janssen Sci Affairs LLC, Horsham, PA USA
[3] Thomas Jefferson Univ, Sidney Kimmel Sch Med, Philadelphia, PA USA
[4] Truven Hlth Analyt, Bethesda, MD USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2493
引用
收藏
页数：3
相关论文
共 50 条
  • [41] COMPARISON OF PATIENT CHARACTERISTICS AND TREATMENT PATTERNS ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS
    Vallejo-Yague, E.
    Burkard, T.
    Moeller, B.
    Finckh, A.
    Burden, A. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 323 - 324
  • [42] UNITED STATES RHEUMATOLOGY PRACTICE BASED REAL-WORLD EVIDENCE OF METHOTREXATE UTILIZATION AND RESPONSE TO THERAPY IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH INTRAVENOUS GOLIMUMAB: 52-WEEK FROM THE AWARE STUDY
    Broadwell, Aaron
    Schechtman, Joy
    Conaway, Douglas
    Kivitz, Alan
    Black, Shawn
    Xu, Stephen
    Langholff, Wayne
    Zazzetti, Federico
    Kafka, Shelly
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 82 - 82
  • [43] COMPARATIVE EFFECTIVENESS OF INTRAVENOUS GOLIMUMAB VS DOSE-ESCALATED INFLIXIMAB IN A REAL WORLD POPULATION OF RHEUMATOID ARTHRITIS PATIENTS: 52-WEEK DATA FROM THE AWARE STUDY
    Schwartzman, Sergio
    Kafka, Shelly
    Conaway, Douglas
    Roadwell, Aaron
    Black, Shawn
    Xu, Stephen
    Langholff, Wayne
    Zazzetti, Federico
    Curtis, Jeffrey R.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 82 - 82
  • [44] Comparative Effectiveness of Intravenous Golimumab vs Dose-Escalated Infliximab in a Real World Population of Rheumatoid Arthritis Patients: 52-Week Data from the AWARE Study
    Schwartzman, Sergio
    Kafka, Shelly
    Conaway, Douglas
    Broadwell, Aaron
    Black, Shawn
    Xu, Stephen
    Langholff, Wayne
    Curtis, Jeffrey R.
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [45] PATIENT CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH UPADACITINIB: THE OM1 RA REGISTRY
    Bergman, M.
    Tundia, N.
    Bryant, A.
    Topuria, I.
    Brecht, T.
    Dunlap, K.
    Gibofsky, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 446 - 447
  • [46] Real World Evidence Describing Infliximab Utilization Patterns in Rheumatoid Arthritis Patients in Community Rheumatology Practices in the United States: Implications for Cost Efficiencies?
    Schwartzman, Sergio
    Parenti, Dennis
    Black, Shawn
    Xu, Stephen
    Langholff, Wayne
    Kafka, Shelly
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [47] IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH GOLIMUMAB: SUB-ANALYSIS OF ASIAN PATIENTS ENROLLED IN PHASE-3 CLINICAL TRIALS
    Tsai, W. C.
    Mu, R.
    Suh, C. H.
    Furtner, D.
    Lo, K. H.
    Zhou, Y.
    Hsia, E. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 447 - 448
  • [48] Patient-Reported Outcomes Measurement Information System (PROMIS) Assessment of Response to Treatment with Golimumab IV or Infliximab in Rheumatoid Arthritis Patients: Results from a Phase 4 Study
    Bingham, Clifton, III
    Kafka, Shelly
    Black, Shawn
    Xu, Stephen
    Langholff, Wayne
    Curtis, Jeffrey R.
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [49] Pre-Treatment Whole Blood Gene Expression Is Associated with 14-Week Response Assessed by Dynamic Contrast Enhanced Magnetic Resonance Imaging in Infliximab-Treated Rheumatoid Arthritis Patients
    MacIsaac, Kenzie D.
    Baumgartner, Richard
    Kang, Jia
    Loboda, Andrey
    Peterfy, Charles
    DiCarlo, Julie
    Riek, Jonathan
    Beals, Chan
    PLOS ONE, 2014, 9 (12):
  • [50] PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH SUBCUTANEOUS TOCILIZUMAB COMPARED WITH PLACEBO OR INTRAVENOUS TOCILIZUMAB IN COMBINATION WITH CSDMARDS
    Strand, V.
    Lampl, K.
    Birchwood, C.
    Pei, J.
    Tuckwell, K.
    Finch, R.
    Kivitz, A.
    Burmester, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 581 - 582
12345